echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Two "fresh faces" rush into top 10 of best selling drugs in 2020: market status and development trend of top 10 in sales list

    Two "fresh faces" rush into top 10 of best selling drugs in 2020: market status and development trend of top 10 in sales list

    • Last Update: 2016-03-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: the drug sales volume of medical economic news 2016-03-11 is often predicted by studying every big change in the market and the result of shocking the industry in important clinical projects In recent years, there are many factors concerned in drug sales forecast For example, in 2015, bio similar drugs entered the U.S market, and many heavy-duty products will be launched in the next few years, which will have a certain impact on the original research bio drug market; payers will continue to increase the demand for discounts, especially in some areas with high market competition, such as hepatitis C, respiratory tract and diabetes drugs What is the growth rate of these drug discounts? How will the new cancer treatment drug reimbursement scheme of pharmacy benefit management companies (PBM), such as express scripts, affect the sales of these drugs? Some research and development projects with clinical results that are warmly concerned by the industry are expected to improve the sales expectation of drugs For example, does the drug safety issues generated by Biogen tecbidera affect its sales? Will the new multiple sclerosis blockbuster drugs cause the same kind of safety issues? Evaluatepharma has been exploring the answers to the above questions, and recently launched the world's top 20 drug sales forecast in 2020 This paper focuses on the top 10 The current market situation and development trend of drugs in the next five years In the top 10 list of best-selling drugs in 2020, "familiar faces" are the most, and there are two "fresh blood" approved in recent two years No.1 sumira reached its peak sales in 2017 Currently, the sales performance of the world's best-selling drug, Humira, will continue until 2020 Some analysts believe it will peak sales in the next few years, after which sales began to decline As for when it will peak, different analysts have different opinions To be sure, abbvie will soon face competition from biologicals Zydus Cadila, an Indian pharmaceutical company, will be one of its rivals, and many other generic companies are salivating over the lucrative "big cake" Analysts at Suntrust believe that with patents in the U.S market, Alberto will remain competitive by 2020 The company will "maximize" the value of its drugs through sales expansion, pricing, indications and dosage form increase Citi analysts predict that Sumeria will decline from 2018, and its sales will fall to $6 billion by 2022, from a peak of $16 billion in 2017 A new injection form of Sumerian for pain relief has just been approved in Europe In September 2015, FDA also approved its use in the treatment of rare skin inflammation indications, and the peak sales of the indications are predicted to reach US $1 billion In 2017, No.2 rifeme reached its peak sales of antitumor drug thalomid (thalidomide), which laid a good foundation for the operation of celgene But now, rifeme, which is used to treat myelodysplastic syndrome, is promoting the rapid development of the enterprise Although new base medicine has expanded its R & D business from specialized drugs for multiple myeloma to Abraxane (Taxol for injection), vidaza (anti leukaemia drug) and otezla (anti-inflammatory disorder drug), its R & D and production lines are all based on the sales of Revlimid In 2015, the sales volume of Rimage reached US $5.8 billion, an increase of 16% over the same period of the previous year Xinji medicine predicts that the sales growth of the drug will reach 15% in 2016, and the sales volume will be about 6.6-6.7 billion US dollars The total annual sales volume of the company's products is predicted to be US $10.5-11 billion, and the share of Rimage is more than 60% At the end of 2015, Xinji pharmaceutical and Indian pharmaceutical company NATCO reached a patent litigation settlement due to the approaching of patent cliff and bio similar drugs NATCO, which will launch its Remix biosimilars in 2022, promised to control the sales volume of biosimilars by 2025 In this way, at least by 2020, rifeme will maintain a strong sales growth momentum At the same time, pomalyst, another new multiple myeloma drug of new base medicine, has gradually established its foothold and achieved sales of 982 million US dollars in 2015 The company's 2017 total sales target is $12 billion and 15% growth No.3 opdivo is far away from its competitors In 2020, the opdivo of Bristol Myers Squibb is likely to become the third best-selling brand new drug in the world, and achieve a sales volume of 8.4 billion US dollars with a rapid sales growth The anti-tumor drug was approved by Christmas 2014, ahead of schedule As an anti-PD-1 immunosuppressive checkpoint inhibitor, opdivo can interfere with a mechanism for tumor cells to evade the recognition of the immune system, and is used in the treatment of many kinds of tumor diseases Initially, the melanoma treatment scheme was approved, and then FDA approved it for the treatment of non-small cell lung cancer It also performed well in clinical trials of end-stage renal tumor treatment, which was more effective than Novartis' afinitor However, Bristol Myers Squibb has greater sales expectations In March 2015, the company announced that it will carry out more than 50 clinical projects for 7000 patients from around the world, test the treatment of multiple tumor types with opdivo, and carry out comprehensive treatment with single therapy or other drugs The increase in the sales curve of opdivo is likely to exceed that of keytruda, the PD-1 inhibitor of MSD The latter was approved three months earlier than the former According to the forecast of evaluatepharma, keytruda's sales in 2020 will be less than $5 billion, ranking 19th In 2015, the high pricing of No.4 harvoni became a bottleneck, and Gilead science and its new hepatitis C drug harvoni gained great market attention Harvoni is the first tablet type hepatitis C cocktail therapy drug in the world Its high cure rate and controllable side effects make it quickly popular in the market However, the drug's 12 week course, priced at $95000, has also been widely criticized and questioned Before that, the Geely de hepatitis C drug sovaldi was also criticized for its high price In 2015, because of a considerable drug discount offered by Albright, the express prescription included viekira Pak in the exclusive drug reimbursement scope of hepatitis C treatment, and excluded the expensive harvoni and sovaldi from the list of hepatitis C drugs The result of this price war is that it can save consumers $4 billion in medical costs every year, and reduce the drug cost per patient by 40% on average At present, the medical insurance system of some states in the United States has begun to refuse to reimburse harvoni's medical expenses, and some patients have taken the action of purchasing drugs from abroad This could slow sales growth in harvoni in the next few years However, as Gilead has gathered a certain scale of hepatitis C "patient bank", its sales potential is only showing "tip of the iceberg" The strong sales growth of two effective hepatitis C drugs is enough to support its creation of more heavy explosives in the next few years Prevnar 13, the No.5 prevnar 13 vaccine market accounts for 17% of Pfizer's heavyweight pneumococcal vaccine, is obviously the best-selling vaccine in the world in 2015, and it will continue to maintain its dominant position in the vaccine field until 2020 Prevnar 13 entered the European and US markets in December 2009 and February 2010, respectively In the following years, prevnar 13 significantly expanded its sales through more treatment use approvals and who prequalification In August 2014, the CDC's Advisory Committee on immunization time recommended the vaccine for people over 65 years of age in the United States, which increased Pfizer's annual sales by about $2 billion In 2015, prevnar 13's franchise generated $6.2 billion in sales, compared with $4.46 billion in 2014 In 2015, the sales growth rate of prevnar 13 in the U.S market was 102%, mainly due to a large number of new adult users, and this trend will continue in 2016 At the same time, Pfizer is also gradually expanding the layout of vaccine market in G7 countries According to analysts' forecast, its market share will occupy up to 17% of the global vaccine market in 2020 No.6 Avastin is facing the threat of cost control Since Avastin was approved to treat colon cancer ten years ago, Roche has made the most of its economic value In August 2014, the drug was approved by FDA for the treatment of cervical cancer A few months later, the FDA approved Avastin in combination with chemotherapy for platinum resistant ovarian tumors So far, the drug has been approved for breast, lung and kidney tumors In 2014, thanks to the support of regulators, Avastin's sales grew by 6% rapidly, filling Roche's first-line revenue In 2015, sales of the drug increased by 9% to about $6.95 billion However, not everything is going well, especially in Europe, where spending is currently being cut Based on cost-effectiveness considerations, the National Institute of health and Clinical Excellence (NICE) has limited the use of Avastin Previously, patients could still get the drug through the British cancer drug Foundation (CDF), which recently announced that in order to reduce costs, it will cancel the reimbursement authority of some drugs It is said that Avastin may exist in the "exclusion list" of CDF No.7 Herceptin has been the third best-selling drug of Roche for 15 years, after Avastin and rituxan Herceptin is the earliest anticancer drug of Roche, mainly for cancer patients with specific genetic characteristics, and Roche has laid the foundation for the development of this specific treatment market Herceptin is aimed at tumor patients with over expression of HER2 gene However, as a leader, Herceptin's sales situation is also declining Mylan and its Indian partner, biocon, have developed and listed generic versions of the drug in India, while celltrion, a South Korean biopharmaceutical company, has approved similar versions of the drug in the country; Hospita, a U.S pharmaceutical company with strong potential in the research and development of biological similar drugs, has laid a foundation in the UK market In its patent litigation with Roche, it is persuading the court to revoke the patent of Roche Herceptin Unless Roche wins the lawsuit, the ruling will immediately open up the market for Herceptin's biological analogues once hospita wins Herceptin's main patent expires on July 28, 2016 No.8 soliris is a new indication Soliris (ekuzumab) is a kind of drug with super high price, which is used to treat a variety of ultra rare diseases For many years, it has been listed as one of the most expensive drugs in the world Even so, its price is still rising Its current market price in the United States is $669000 per year Because the diseases soliris treats are rare, payers tend to be willing to reimburse more for their medicines However, alexion also encountered some obstacles: alexion sued for trying to suppress the price of soliris in the Canadian market; meanwhile, British regulators working on cost-effective improvement asked alexion for the R & D and production of the drug
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.